22 February 2023 – PLC congratulates ARS Pharmaceuticals on their recent reacquisition of the European marketing rights to neffy®. Regulatory and clinical development of neffy has been supported by PLC in the US and overseas since program inception. neffy is a needle-free Epinephrine treatment for Type I allergic reactions including anaphylaxis. NDA and MAA reviews for this Epinephrine nasal spray are underway with the FDA and EMA, respectively.
ARS Pharmaceuticals Reacquires European Marketing Rights to neffy® (ARS-1) for the Treatment of Type I Allergic Reactions Including Anaphylaxis
